{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T22:10:51Z","timestamp":1775859051766,"version":"3.50.1"},"reference-count":21,"publisher":"Japanese Society for Lymphoreticular Tissue Research","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCEH","J Clin Exp Hematopathol"],"published-print":{"date-parts":[[2022]]},"DOI":"10.3960\/jslrt.22018","type":"journal-article","created":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T22:15:59Z","timestamp":1664316959000},"page":"181-186","source":"Crossref","is-referenced-by-count":8,"title":["Successful treatment with tirabrutinib for relapsed Bing-Neel                    syndrome following high-dose methotrexate and craniospinal                    irradiation"],"prefix":"10.3960","volume":"62","author":[{"given":"Masuho","family":"Saburi","sequence":"first","affiliation":[{"name":"Department of Hematology, Oita Prefectural                            Hospital, Oita, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanori","family":"Sakata","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oita Prefectural                            Hospital, Oita, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuki","family":"Okuhiro","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and                            Hematology, Faculty of Medicine, Oita University, Oita, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuya","family":"Kawano","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory Technology,                            Oita Prefectural Hospital, Oita, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Souhei","family":"Uesugi","sequence":"additional","affiliation":[{"name":"Department of Neurology, Oita Prefectural                            Hospital, Oita, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junpei","family":"Wada","sequence":"additional","affiliation":[{"name":"Department of Pathology, Oita Prefectural                            Hospital, Oita, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shogo","family":"Urabe","sequence":"additional","affiliation":[{"name":"Department of Pathology, Oita Prefectural                            Hospital, Oita, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshio","family":"Saburi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oita Prefectural                            Hospital, Oita, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiichi","family":"Ohtsuka","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oita Prefectural                            Hospital, Oita, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2349","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Minnema                            MC,                                Kimby                            E,                                D\u2019Sa                            S                    <i>et al.<\/i> Guideline for the diagnosis, treatment and response                    criteria for Bing-Neel syndrome. Haematologica. 2017; 102:                    43-51.","DOI":"10.3324\/haematol.2016.147728"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Castillo                            JJ,                                D\u2019Sa                            S,                                Lunn                            MP                    <i>et al.<\/i> Central nervous system involvement by Waldenstr\u00f6m                    macroglobulinaemia (Bing-Neel syndrome): a multi-institutional retrospective                    study. Br J Haematol. 2016; 172: 709-715.","DOI":"10.1111\/bjh.13883"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Simon                            L,                                Fitsiori                            A,                                Lemal                            R                    <i>et al.<\/i> Bing-Neel syndrome, a rare complication of Waldenstr\u00f6m                    macroglobulinemia: analysis of 44 cases and review of the literature. A study on                    behalf of the French Innovative Leukemia Organization (FILO). Haematologica.                    2015; 100: 1587-1594.","DOI":"10.3324\/haematol.2015.133744"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Castillo                            JJ,                                Treon                            SP. How we                    manage Bing-Neel syndrome. Br J Haematol. 2019; 187: 277-285.","DOI":"10.1111\/bjh.16167"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Sekiguchi                            N,                                Rai                            S,                                Munakata                            W                    <i>et al.<\/i> A multicenter, open-label, phase II study of                    tirabrutinib (ONO\/GS-4059) in patients with Waldenstr\u00f6m\u2019s macroglobulinemia.                    Cancer Sci. 2020; 111: 3327-3337.","DOI":"10.1111\/cas.14561"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Sekiguchi                            N,                                Rai                            S,                                Munakata                            W                    <i>et al.<\/i> Two-year outcomes of tirabrutinib monotherapy in                    Waldenstr\u00f6m\u2019s macroglobulinemia. Cancer Sci. 2022; 113:                    2085-2096.","DOI":"10.1111\/cas.15344"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Saburi                            M,                                Saburi                            Y,                                Kawano                            K                    <i>et al.<\/i> Successful treatment with tirabrutinib for relapsed                    lymphoplasmacytic lymphoma complicated by Bing-Neel syndrome. Int J Hematol.                    2022; 115: 585-589.","DOI":"10.1007\/s12185-021-03246-z"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Oyama                            T,                                Taoka                            K,                                Chiba                            A                    <i>et al.<\/i> A case of Bing-Neel syndrome successfully treated with                    tirabrutinib. Intern Med. 2022; [Online ahead of print].","DOI":"10.2169\/internalmedicine.9545-22"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Swerdlow                            SH,                                Campo                            E,                                Pileri                            SA                    <i>et al.<\/i> The 2016 revision of the World Health Organization                    classification of lymphoid neoplasms. Blood. 2016; 127:                    2375-2390.","DOI":"10.1182\/blood-2016-01-643569"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Kulkarni                            T,                                Treon                            SP,                                Manning                            R                    <i>et al.<\/i> Clinical Characteristics and treatment outcome of CNS                    involvement (Bing-Neel syndrome) in Waldenstrom\u2019s macroglobulinemia. Blood.                    2013; 122: 5090.","DOI":"10.1182\/blood.V122.21.5090.5090"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Treon                            SP,                                Xu                            L,                                Yang                            G                    <i>et al.<\/i> MYD88 L265P somatic mutation in Waldenstr\u00f6m\u2019s                    macroglobulinemia. N Engl J Med. 2012; 367: 826-833.","DOI":"10.1056\/NEJMoa1200710"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Yang                            G,                                Zhou                            Y,                                Liu                            X                    <i>et al.<\/i> A mutation in MYD88 (L265P) supports the survival of                    lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenstr\u00f6m                    macroglobulinemia. Blood. 2013; 122: 1222-1232.","DOI":"10.1182\/blood-2012-12-475111"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Treon                            SP,                                Tripsas                            CK,                                Meid                            K                    <i>et al.<\/i> Ibrutinib in previously treated Waldenstr\u00f6m\u2019s                    macroglobulinemia. N Engl J Med. 2015; 372: 1430-1440.","DOI":"10.1056\/NEJMoa1501548"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Treon                            SP,                                Gustine                            J,                                Meid                            K                    <i>et al.<\/i> Ibrutinib monotherapy in symptomatic, treatment-na\u00efve                    patients with Waldenstr\u00f6m macroglobulinemia. J Clin Oncol. 2018; 36:                    2755-2761.","DOI":"10.1200\/JCO.2018.78.6426"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Cabannes-Hamy                            A,                                Lemal                            R,                                Goldwirt                            L                    <i>et al.<\/i> Efficacy of ibrutinib in the treatment of Bing-Neel                    syndrome. Am J Hematol. 2016; 91: E17-E19.","DOI":"10.1002\/ajh.24279"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Mason                            C,                                Savona                            S,                                Rini                            JN                    <i>et al.<\/i> Ibrutinib penetrates the blood brain barrier and shows                    efficacy in the therapy of Bing Neel syndrome. Br J Haematol. 2017; 179:                    339-341.","DOI":"10.1111\/bjh.14218"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Castillo                            JJ,                                Itchaki                            G,                                Paludo                            J                    <i>et al.<\/i> Ibrutinib for the treatment of Bing-Neel syndrome: a                    multicenter study. Blood. 2019; 133: 299-305.","DOI":"10.1182\/blood-2018-10-879593"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Wong                            J,                                Cher                            L,                                Griffiths                            J                    <i>et al.<\/i> Efficacy of zanubrutinib in the treatment of Bing-Neel                    syndrome. HemaSphere. 2018; 2:                    e155.","DOI":"10.1097\/HS9.0000000000000155"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Abrey                            LE,                                DeAngelis                            LM,                                Yahalom                            J. Long-term                    survival in primary CNS lymphoma. J Clin Oncol. 1998; 16:                    859-863.","DOI":"10.1200\/JCO.1998.16.3.859"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Omuro                            AMP,                                Ben-Porat                            LS,                                Panageas                            KS                    <i>et al.<\/i> Delayed neurotoxicity in primary central nervous system                    lymphoma. Arch Neurol. 2005; 62: 1595-1600.","DOI":"10.1001\/archneur.62.10.1595"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Narita                            Y,                                Nagane                            M,                                Mishima                            K                    <i>et al.<\/i> Phase I\/II study of tirabrutinib, a second-generation                    Bruton\u2019s tyrosine kinase inhibitor, in relapsed\/refractory primary central                    nervous system lymphoma. Neuro-oncol. 2021; 23: 122-133.","DOI":"10.1093\/neuonc\/noaa145"}],"container-title":["Journal of Clinical and Experimental Hematopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/62\/3\/62_22018\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T05:20:31Z","timestamp":1664601631000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/62\/3\/62_22018\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.3960\/jslrt.22018","relation":{},"ISSN":["1346-4280","1880-9952"],"issn-type":[{"value":"1346-4280","type":"print"},{"value":"1880-9952","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022]]},"article-number":"22018"}}